$RENB (NASDAQ: RENB), GEDICube announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. GEDiCube is committed to the early detection of cancer Cyclomics’ Omni-Omic 4th generation technology, we believe, will disrupt the cancer diagnostics market and clinical practice by enabling fast and reliable results and delivering superior performance to standard radiological and physical examination alone.